Phibro’s (PAHC) Big Acquisition Bet Just Cleared Its First Full Year

finance.yahoo.com · 2026-09-01

Phibro Animal Health (NASDAQ:PAHC) closed out fiscal 2026 with numbers that speak for themselves. Full-year net sales topped $1.5 billion, adjusted EBITDA climbed 39% to $255 million, and adjusted diluted earnings per share jumped 48% to $3.22. The results, covering the quarter and year ended June 30, mark the first complete fiscal year since the […]

TickrTrends take: Phibro Animal Health has now completed its first full year following a significant acquisition, providing investors with the initial results needed to assess whether the company paid a fair price for the deal. Given TickrTrends' current assessment that PAHC trades at an undervalued level, readers should monitor whether the acquired assets generate sufficient earnings and cash flow to justify the acquisition price and support any multiple expansion. The healthcare sector investor watching this stock should track whether management's integration efforts translate into margin improvements or revenue synergies that could narrow any valuation gap.

Read the full story at finance.yahoo.com →